Moreover, the association between more frequent TP53 mutations in HR-negative patients has been also previously demonstrated in plasma sequencing from BC cancer patients [22,23], where the authors pointed certain implications in response to anti-HER2 treatments. This evidence concerns the gene ERBB2 and cancer.